Dabigatran: The Anticoagulant We have Long Expected?

Author(s): Georgios I. Tagarakis, Dimos Karangelis, Marios E. Daskalopoulos, Nikolaos B. Tsilimingas

Journal Name: Recent Patents on Cardiovascular Drug Discovery
Continued as Recent Advances in Cardiovascular Drug Discovery

Volume 5 , Issue 3 , 2010


Many researchers have until now united their efforts in the endeavor to discover new anticoagulants, which would be simpler to use and safer to administer, so that patients would avoid both thromboembolic events as well as life threatening episodes of bleeding. One of these agents, that is hereby presented along with patents, is dabigatran, which promises much for the future, despite the fact that time and the awaited results of ongoing trials will be necessary for its establishment as a first-line anticoagulant. More specifically, based on the major trials of RELY and RECOVER, we could state that dabigatran has presented satisfactory outcomes in terms of bleeding and prevention of venous thromboembolism.

Keywords: Dabigatran, anticoagulant, &, prevention, thromboembolism, cumarin, warfarin, paroxysmal atrial fibrillation, prosthetic heart valves, thrombogenesis, antithrombotic agents, C34H41N7O5, serine proteases, trypsin, glucuronidation, vitamin K epoxide reductase, Dyspepsia, proton-pump inhibitors, omeprazole, esomeprazole, pantoprazole, myocardial infarct, venography, hip replacement, Coumadin, Pradax, Enoxaparin, inhibition of thrombin, Antidote, knee replacement, intracranial hemorrhages

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Published on: 01 March, 2012
Page: [223 - 226]
Pages: 4
DOI: 10.2174/157489010793351926
Price: $65

Article Metrics

PDF: 3